Nonalcoholic Steatohepatitis Therapeutics Market: Global Size, Share, Trends, Growth and Forecast, 2022-2032
Nonalcoholic Steatohepatitis Therapeutics Market: Overview and Definition
Nonalcoholic Steatohepatitis (NASH) is a chronic liver disease characterized by the accumulation of fat in the liver, inflammation, and damage to liver cells. NASH is considered a severe form of nonalcoholic fatty liver disease (NAFLD) and is often associated with obesity, diabetes, and metabolic syndrome.
The Nonalcoholic Steatohepatitis Therapeutics market refers to the development and commercialization of drugs and therapies to treat NASH. NASH therapeutics aim to reduce liver inflammation, prevent liver fibrosis, and improve liver function in patients with NASH.
The NASH therapeutics market is driven by the growing prevalence of NASH, which is becoming a significant public health concern worldwide. According to the National Institute of Diabetes and Digestive and Kidney Diseases, NASH affects an estimated 16 million people in the United States alone. There are currently no FDA-approved drugs for the treatment of NASH, and the market is highly competitive, with numerous companies working on the development of NASH therapies.
The NASH therapeutics market includes a range of approaches, including small molecule drugs, biologics, and gene therapies. Therapeutic targets for NASH include liver inflammation, fibrosis, and metabolic dysfunction, and many of the drugs in development target these pathways.
The NASH therapeutics market is also influenced by factors such as regulatory requirements, clinical trial design, and the availability of funding for NASH research and development. The market is expected to continue growing as new therapies are developed and as the prevalence of NASH continues to increase.
The global nonalcoholic steatohepatitis therapeutics market size is estimated to be USD XXX Million in 2021 and is expected to reach USD XXX Million by 2032, growing at a compound annual growth rate (CAGR) of XX.X% during the forecast period i.e., 2022-2032.
Nonalcoholic Steatohepatitis Therapeutics Market: Growth Drivers
Rise in Number of Cases of Diabetes and Obesity
In the past years, the cases of people suffering from diabetes and obesity have increased at an alarming rate. In the North American region, there is a large population suffering from obesity and diabetes. Not only the adults but the children's are also considered to be suffering from obesity, which has increased almost three times compared to the past year. Due to which there is an increase in demand for treatment of such diseases, which is expected to propel the growth of nonalcoholic steatohepatitis therapeutics over the upcoming years.
Nonalcoholic Steatohepatitis Therapeutics Market: Segmentation Analysis
The nonalcoholic steatohepatitis therapeutics market is segmented by drug type. Based on drug type, the market is segmented into cenicriviroc, emricasan, elafibranor, ocaliva, selonsertib, and others, out of which, elafibranor segment is anticipated to grow at a significant CAGR over the forecast period i.e., 2020-2025. Further, it was followed by ocaliva segment in terms of market share in 2019.
Nonalcoholic Steatohepatitis Therapeutics Market: Geographical Analysis
Geographically, the report offers an analysis of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the nonalcoholic steatohepatitis therapeutics market, North America is anticipated to capture a notable market share in 2025. Further, factors such as rise in population suffering from obesity and diabetes in the region are expected to drive the growth of North America nonalcoholic steatohepatitis therapeutics market. Also, the North America market is driven on the back of prevailing cases of high cholesterol and is projected to grow at a noteworthy compound annual growth rate (CAGR) from 2020 to 2025.
Nonalcoholic Steatohepatitis Therapeutics Market: Competitive Analysis
The report also covers detailed competitive analysis of major market players of global nonalcoholic steatohepatitis therapeutics market, such as GENFIT SA, Gilead Sciences, Inc., Immuron Ltd., Astrazeneca Plc, Conatus Pharmaceuticals, Tobira Therapeutics, Inc., Zydus Cadila, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Novo Nordisk A/S and other major & niche players. The global nonalcoholic steatohepatitis therapeutics market is witnessing a wide range of industry activities such as product launch, acquisition, partnership, and expansion across the globe.
By Drug Type:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)
The report profiles various major market players such as
• GENFIT SA
• Gilead Sciences, Inc.
• Immuron Ltd.
• Astrazeneca Plc
• Conatus Pharmaceuticals
• Tobira Therapeutics, Inc.
• Zydus Cadila
• Galmed Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Novo Nordisk A/S
• Other Major & Niche Players
Competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, company overview, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, technology development, research & development and other market activities).
The study also provides company’s positioning and market share in nonalcoholic steatohepatitis therapeutics market.
Timeline Considered for Analysis:
- 2019: Base Year
- 2020: Estimated Year
- 2020 to 2025: Forecast Period
Research Scope and Deliverables
Overview & Executive Summary
Market Drivers, Trends, Challenges and Opportunities
Market Size and Forecast Projections
Macroeconomic Indicators of Various Countries Impacting the Growth of the Market
Extensive Coverage of Industry Players including Recent Product Launches and Market Activities
Porter’s Five Force Analysis
Market Segmentation Analysis:
Industry report analyzes the global nonalcoholic steatohepatitis therapeutics market by the following segments:
- Drug Type
Customization: We also offers customization’s in the industry report as per the company’s specific needs.
Key Questions Answered in the Global Nonalcoholic Steatohepatitis Therapeutics Industry Report
• What is the overall market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?
• Which region would have high demand for product in the upcoming years?
• What are the factors driving the growth of the market?
• Which sub-market will make the most significant contribution to the market?
• What are the market opportunities for existing and entry-level players?
• What are various long-term and short-term strategies adopted by the market players?